Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma August 03, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc. CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the completion …
Praxis Precision Medicines Announces $110 Million Financing
Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio July 28, 2020 08:59 AM Eastern Daylight Time CAMBRIDGE, Mass.–BUSINESS WIRE–Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system disorders, today announced that it has raised approximately $110 million …
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
February 21, 2020 09:00 ET | Source: Avadel Pharmaceuticals plc DUBLIN, Ireland, Feb. 21, 2020 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it entered into a definitive …
Allogene Therapeutics Completes a $120 Million Private Financing
SOUTH SAN FRANCISCO, Calif.–BUSINESS WIRE–Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced it has completed a $120 million private financing of Convertible Notes. Participants in this financing were primarily first-time investors in Allogene. The financing was led by Perceptive Advisors and included Deerfield Management …
Apellis Pharmaceuticals Announces $60 Million Series E Financing
Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria LOUISVILLE, KY., August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred stock financing led by Sectoral Asset Management. New …
+1 212.937.4970
info@avorocapital.com